 |
|
Association Between Apolipoprotein E 4 and the Rate of Cognitive Decline in Community-Dwelling Elderly Individuals With and Without Dementia
Cees Jonker, MD, PhD;
Ben Schmand, PhD;
Jaap Lindeboom, PhD;
Louis M. Havekes, PhD;
Lenore J. Launer, PhD
Arch Neurol. 1998;55:1065-1069.
ABSTRACT
| |
Objective To determine whether the apolipoprotein E  4 allele (apoE 4) is associated with cognitive decline in individuals with and without dementia, we conducted a 4-year longitudinal study of subjects with a range of cognitive function.
Setting At baseline, respondents (n=511) were randomly selected according to age and Mini-Mental State Examination score from a community-based study of dementia among noninstitutionalized persons aged 65 to 84 years. Respondents were examined at baseline and followed up in 3 annual visits. At baseline, subjects were classified as having normal cognitive function, minimal dementia, or dementia, according to criteria from the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) and the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition . Of the 511 respondents at baseline, 405 who were examined at least 2 times are included in this analysis.
Main Outcome Measures Cognitive decline was determined by a slope estimating yearly change in score on the neuropsychological test, the CAMCOG (the cognitive section of the CAMDEX), and its subscales of memory and nonmemory functions.
Results Among the subjects who had normal cognitive function at baseline, apoE 4 carriers showed a significantly greater decline (P<.001) in score on the CAMCOG compared with noncarriers. Differences in decline on the memory and nonmemory subtests were also significant (P<.001). Rates of cognitive decline were not related to apoE 4 status in the groups with minimal dementia and dementia.
Conclusions In our community-based sample, apoE 4 was associated with the rate of cognitive decline prior to the clinically symptomatic phase of dementia. Knowing the apoE 4 status of those already symptomatic for dementia may not improve knowledge about a patient's prognosis.
INTRODUCTION
ALTHOUGH the apolipoprotein E 4 allele (apoE 4) has been repeatedly demonstrated to be a risk factor for sporadic and familial Alzheimer disease (AD),1-3 the mechanisms by which the allele may alter the risk for dementia are not well understood. One indication of how apoE 4 may be involved in the disease process is the extent to which the allele is associated with or prognostic for disease progression in the subclinical and clinical stages of AD.
Three diagnostic groups have formed the basis of studies on the progression of cognitive decline and dementia in relation to apoE 4 : individuals with normal cognitive function, those with mild cognitive impairment, and those with clinically evident dementia. The few population-based studies of community-dwelling elderly individuals suggest that apoE 4 is associated with a greater risk for cognitive decline and dementia.4-6 Studies of subjects with minimal dementia and dementia have been mostly clinic based; some studies, in particular those of individuals with minimal dementia, show an association between apoE 4 and the progression of dementia,7-9 while others do not.10-16 These conflicting results might be related to selection biases or to differences in the stages of the disease included in the various clinical samples. This makes comparisons across diagnostic subgroups difficult.
In this study, we compared rates of cognitive decline with apoE 4 status in subjects with normal cognitive function, minimal dementia, and dementia. All subjects were selected from the same source population of community-dwelling persons aged 65 to 84 years. We also investigated whether the apoE 4 allele was differentially associated with a decline in memory and nonmemory functions, as has previously been suggested.17
SUBJECTS AND METHODS
DESIGN
Subjects were participants in the Amsterdam Study of the Elderly, a 2-phase study on cognitive decline and dementia in community-dwelling elderly individuals. The design and sampling methods of the study are described in more detail elsewhere.18-19 Briefly, a random age-stratified (65-84 years in 5-year strata) sample was selected from the lists of 30 general medical practices in the municipality of Amsterdam. A total of 4051 subjects (71.5% response rate) participated in this cross-sectional study. Subjects were visited at home by trained lay interviewers, who administered, among other items, the Mini-Mental State Examination (MMSE).20
From the sample of 4051 subjects, we excluded those (n=95) who were nearly blind, deaf, or did not have a thorough command of the Dutch language. From the remaining 3956, we invited for follow-up all respondents (n=156) who scored less than 22 points on the MMSE, a random age-stratified sample of approximately 45% (n=416) of subjects with borderline (22-26 points) scores on the MMSE, and a random age-stratified sample of approximately 7% (n=215) of subjects with good (27-30 points) MMSE scores. We oversampled those with borderline cognitive function, since 1 objective of the follow-up study was to better characterize individuals with mild cognitive impairment. Of the total 787 subjects who were invited, 511 participated in the follow-up study. Compared with the respondents, the nonrespondents to the follow-up study did not differ in age, sex distribution, MMSE score, or years of education.
The respondents were examined at baseline and then visited annually for 3 years. During these visits, the diagnostic procedure for dementia was administered. Blood was drawn at baseline. There were 485 subjects with complete baseline data and 405 subjects with complete data from at least 2 examinations.
ANALYTIC SAMPLE
Dropout in the follow-up study did not affect the proportion of subjects with the 4 allele, which was 30.6% (n=148) (SE, 2.3%) in the total sample at baseline and 28.0% (n=71) (SE, 3.0%) in the group of 254 subjects who participated through the end of the study. In addition, the proportion of subjects with the apoE 4 allele did not change within the 3 diagnostic groups. Dropouts did not differ by sex or years of education, although they were significantly older (78.4 years [SE, 4.8 years] vs 75.7 [SE, 5.7 years]; P <.001). Although the individuals without dementia at baseline had proportionately more visits (mean±SD visits for subjects without dementia, with minimal dementia, and dementia were 3.5±0.8, 3.3±0.8, and 3.1±0.7, respectively; P=.005), within the diagnostic groups there were no differences in the number of visits according to apoE 4 status. The analytic sample for the study of cognitive decline included the 405 subjects who had at least 2 scores on the CAMCOG.
DIAGNOSIS OF DEMENTIA
At each visit, a physician and nurse from the study assessed dementia with the protocol of the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX).21 The CAMDEX includes an interview with the participant and, if possible, an informant, a physical examination, and a cognitive section (the CAMCOG). The diagnoses of dementia and its subtypes were made in conference under the supervision of a senior psychiatrist and neurologist. Diagnoses for dementia were based on criteria from the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition,22 and diagnoses of AD were based on the NINCDS-ADRDA (National Institute of Neurological Disorders and Stroke–Alzheimer's Disease and Related Disorders Association).23 For these analyses, respondents were classified as having normal cognitive function, minimal dementia (according to CAMDEX), or dementia. The CAMDEX category of minimal dementia includes subjects who show unmistakable cognitive symptoms (mostly amnestic symptoms) but do not yet satisfy the criteria for dementia in the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. The diagnosis of minimal dementia is comparable to a Clinical Dementia Rating24 of 0.5 (questionable dementia).
COGNITIVE STATUS
Cognitive function and decline were measured with the CAMCOG. This is a 60-item omnibus test of orientation in time and place, learning, recent and remote memory, attention, visual and tactile perception, praxis, calculation, receptive and expressive language functions, and verbal abstraction. The CAMCOG includes the MMSE.20 The maximum CAMCOG score is 107 points. For the present analysis, the CAMCOG was divided into memory and nonmemory subscales. The memory subscale includes questions about orientation, learning, and memory; the nonmemory subscale includes the remaining questions on language function, attention, praxis, calculation, verbal abstraction, and perception.
apoE PHENOTYPING
In the first year, blood was sampled and plasma was stored at -80°C. Apolipoprotein E phenotypes were determined by isoelectric focusing of delipidated plasma samples, followed by immunoblotting.25
DATA ANALYSIS
We included in the group without apoE 4 those with the phenotypes 2/2, 2/3, and 3/3; carriers included those with at least 1 4 allele, ie, with the phenotypes 2/4, 3/4, or 4/4. The cross-sectional comparisons of demographic variables, MMSE scores, CAMCOG scores, and apoE phenotypes by diagnostic group were done with analysis of variance for continuous variables and the  2 test for categorical variables. Age-adjusted odds ratios (95% confidence interval [CI]) for apoE 4 allele dose and prevalent and incident dementia were calculated with logistic regression. The relation of cognitive decline to apoE 4 status and diagnostic group was examined using multiple regression.
Cognitive decline was expressed as a slope and calculated for each individual using a linear model with the visit number (1-4) as the independent variable and the cognitive score obtained at each visit as the dependent variable. Separate slopes were calculated for the total CAMCOG score, memory subscore, and nonmemory subscore. Each subject's slope was then entered as the dependent variable into the separate linear regression models. Controlling for years of education and age at baseline, we then used analysis of variance to examine the difference in slope by apoE status, diagnostic group, and apoE 4 allele status within the diagnostic groups. The analysis of the slope by apoE 4 allele status within the diagnostic group was used to test whether the relation between apoE 4 status and cognitive decline differed among the 3 diagnostic groups. We first tested this difference for statistical significance by entering into the model an interaction term, which is the product of a diagnostic group multiplied by apoE status. We then compared in the separate strata of each diagnostic group the difference in the slope of the cognitive test score by apoE status. The above comparisons were also examined with a random effects model that accounts for unequal numbers of observations per person over time.26 Both methods resulted in the same conclusions concerning the importance of the interaction, ie, concerning the differences in cognitive decline by apoE status across diagnostic group.
RESULTS
The diagnostic groups differed significantly in demographic characteristics and cognitive test variables at baseline (Table 1). The subgroups with dementia and minimal dementia included more women, older subjects, and those with slightly fewer years of education than those in the subgroup with normal cognitive function. Individuals in the group with dementia had the lowest cognitive scores, and those in the group with minimal dementia had scores in between those of individuals with and without dementia. The proportion of apoE 4 allele carriers was significantly higher in the subgroups with minimal dementia and dementia compared with the subgroup with normal cognitive function.
|
|
|
|
Table 1. Demographic Characteristics, Baseline Test Scores, and Cognitive Decline per Year by Diagnostic Group: The AMSTEL Study*
|
|
|
Most (74.4% [n=32]) of the 43 patients with dementia had been diagnosed as having AD, and 62.5% (n=20) of patients with AD were 4 allele carriers, compared with only 9.1% (n=1) of patients with other types of dementia (P=.002).
The age-adjusted odds ratio for prevalent dementia associated with the 4 allele was 2.65 (95% CI, 1.53-4.60). During the course of the study, 34 subjects were diagnosed as having dementia, 8 from the group with normal cognitive function at baseline and 26 from the group with minimal dementia. The age-adjusted odds ratio for incident dementia associated with an apoE 4 allele was 2.66 (95% CI, 1.27-5.58). Among subjects with normal cognitive function at baseline, the age-adjusted odds ratio for incident dementia associated with apoE 4 was 1.89 (95% CI, 0.43-4.37). Among those with minimal dementia, the age-adjusted odds ratio for incident dementia was 3.31 (95% CI, 0.94-11.59). The age-adjusted odds ratio associated with apoE 4 for patients with incident and prevalent AD combined was 3.62 (95% CI, 1.54-8.53).
In the overall analysis, the rate of decline in all 3 cognitive scores differed significantly by diagnostic subgroup, irrespective of 4 status (P<.001).
Table 2 shows the annual decline in the 3 cognitive scores of 4 allele carriers and noncarriers within the 3 diagnostic subgroups. The interaction between apoE status and diagnostic group was significant for the total CAMCOG (P=.002). This significant interaction reflected the finding that in the group with normal cognitive function, the 4 allele carriers declined significantly more than non-4 carriers. There remained a significant decline in cognitive score among the group with normal cognitive function even after all patients with incident minimal (n=35) and clinical (n=8) dementia were excluded from the analysis (the mean decline in score for 4 carriers and noncarriers was -1.35 [95% CI, -1.79 to 0.91] and -0.40 [95% CI, 0.64 to -0.16], respectively).
|
|
|
|
Table 2. Cognitive Decline in 3 Diagnostic Groups by apoE Status: The AMSTEL Study*
|
|
|
In contrast to the findings for subjects with normal cognitive function, there were no significant differences in the declines of cognitive test scores between 4 allele carriers and noncarriers in the minimal dementia and dementia subgroups. The results were similar when all patients with dementia but without AD were removed from the group with dementia. When all patients with prevalent (n=27) and incident (n=25) AD were grouped (n=52), there was a nonsignificant difference between carriers and noncarriers (P>.05). The rate of decline in the non-4 carrier group with AD was -4.09 (95% CI, -4.76 to -3.41), and that in the 4 carrier group with AD was -4.36 (95% CI, -4.94 to -3.77).
The same pattern seen with the analyses of the total CAMCOG scores was evident for the memory (P=.03) and nonmemory (P=.02) subscales. Among the subjects with normal cognitive function, decline was significantly greater in both the memory and nonmemory sections of the CAMCOG (Table 2). There was no difference in decline by 4 status within the minimal dementia and dementia groups.
COMMENT
We found that during an average period of 3 years, apoE 4 allele carriers who had normal cognitive function at baseline had a significantly greater cognitive decline compared with noncarriers.
In contrast, we did not find a faster cognitive decline in symptomatic 4 allele carriers compared with noncarriers. In these analyses, the association of apoE 4 with cognitive decline was not limited to memory-related functions, as has been suggested by Bondi et al.17
There are several methodological issues that might have affected our findings. First, ceiling or floor effects on the tests might have influenced our ability to detect changes in the different diagnostic groups. This is less likely to be a problem with the 107-point CAMCOG used as an outcome than with a shorter mental status test. The CAMCOG has a high ceiling, with very few people scoring 100%. In addition, the scores are well distributed, even among individuals with dementia (range in score, 29-77).
A second issue is related to the characteristics of the subjects who dropped out over the 4-year period. Dropout would have altered the results if it had affected the proportion of apoE 4 carriers, which was not the case. The proportions of 4 allele carriers at baseline and at the end of the study were not significantly different. However, not all individuals with the 4 allele will develop dementia or decline cognitively. If there was a disproportionate dropout of nonsusceptible 4 carriers, which seems unlikely, it would explain the differences in the group with normal cognitive function. Third, the small sample size in the minimal dementia and dementia groups might have affected the results. However, combining the 2 groups did not change the conclusions. In addition, including the patients with incident AD did not change the conclusions. Finally, it is possible that the findings in the normal cognitive function group mainly reflected the decline of individuals who were in the very early stages of dementia. Although it is difficult to completely identify presymptomatic individuals, we did remove those with minimal dementia at baseline and those who subsequently developed minimal or clinical dementia during follow-up.
When the patients with incident AD were removed from the normal cognitive function group, the mean decline in CAMCOG score was lower, but the difference between the carriers and noncarriers of 4 remained significant (P<.001). However, we could not account for incident cases among those who dropped out before the end of the follow-up period.
To our knowledge, this is the first study that compares the rate of cognitive decline associated with 4 status across diagnostic groups of individuals selected from the same source population. This comparison removes some of the barriers to interpreting the results of various studies based on patient groups identified in different ways, at different stages of dementia, and whose progression is evaluated with different instruments. This study has the advantage of including subjects identified in a community-based survey and providing an internally valid comparison of groups at different stages of dementia. Furthermore, we were able to collect data multiple times over a 4-year period, thus allowing us to estimate more reliably the rates of cognitive decline in the sample.
Our findings of the risk for incident dementia (mainly AD) associated with 4 are consistent with those reported by Petersen and colleagues7 in a sample of individuals with memory impairment and by Evans et al27 in a sample of community residents. Our finding of a lack of association between apoE 4 and cognitive decline in symptomatic subjects is consistent with findings from recent clinical studies of patients with AD.10-16
In summary, the results of this study suggest that once cognitive symptoms are manifest, 4 allele dose cannot predict an expected rate of cognitive decline, as some authors suggest.28-30 Thus, the role of apoE 4 in the development of AD might be less direct than has been suggested.1, 31-33
Views on the role of 4 in the cascade of neuropathological processes in AD, in particular around the time of clinical onset, may have to be reconsidered in light of findings from this and previous studies. Our study suggests that the pathophysiological mechanism of apoE 4 may more strongly affect the timing of the onset of the disease than the progression of the disease once the clinical threshold is reached. This is consistent with Roses'34 suggestion that the primary disease process becomes autocatalytic when symptoms first appear. Another possibility suggested by Plassman and Breitner35 is that massive loss of primary targets of the disease process induces secondary degeneration of neural structures. Such degeneration might produce rapid decline in cognitive performance, not necessarily influenced by apoE 4. Finally, this study supports the suggestion that at present, apoE 4 genotyping has few practical consequences for the diagnostic processes, management, and care of symptomatic patients.36
AUTHOR INFORMATION
Accepted for publication December 21, 1997.
The Amsterdam Study of the Elderly (AMSTEL) is supported by grants from the Netherlands Health Research Promotion Programme, the Hague, and the National Fund of Mental Health, Utrecht, the Netherlands.
We are grateful to Piet Eikelenboom, MD, PhD, for his comments on an earlier draft of this article.
Reprints: Cees Jonker, MD, PhD, AMSTEL-project, Faculteit SCW, Vrije Universiteit, De Boelelaan 1081, 1081 HV Amsterdam, the Netherlands (e-mail: C.Jonker{at}scw.vu.nl).
From the Department of Psychiatry and the Institute of Extramural Health Research (Drs Jonker, Schmand, and Lindeboom) and the Department of Medical Psychology (Dr Lindeboom), Free University, and Slotervaart Hospital (Dr Schmand), Amsterdam; Dutch Organization for Applied Scientific Research, Gaubius Laboratory, Leiden (Dr Havekes); the National Institute of Public Health and Environment, Bilthoven; and the Department of Epidemiology and Biostatistics, Erasmus University, Rotterdam (Dr Launer), the Netherlands.
REFERENCES
| |
1. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to ß-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981.
FREE FULL TEXT
2. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
FREE FULL TEXT
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
FREE FULL TEXT
4. Feskens EJM, Havekes LM, Kalmijn S, Launer LJ, Kromhout D. Apolipoprotein E 4 allele and cognitive decline in elderly men. BMJ. 1994;309:1202-1206.
FREE FULL TEXT
5. Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele 4, dementia, and cognitive decline in a population sample. Lancet. 1995;346:1387-1390.
FULL TEXT
|
ISI
| PUBMED
6. Hyman BT, Gomez-Isla T, Briggs M, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol. 1996;40:55-66.
FULL TEXT
|
ISI
| PUBMED
7. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
FREE FULL TEXT
8. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology. 1996;46:661-665.
FREE FULL TEXT
9. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46:149-154.
FREE FULL TEXT
10. Dal Forno G, Rasmusson X, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol. 1996;53:345-350.
FREE FULL TEXT
11. Sarochan M, Förstl H, Sattel H, Zerfass R, Czech C, Beyreuther K. Apolipoprotein E genotype does not promote the clinical progression of manifest Alzheimer's disease [letter]. Dementia. 1996;7:120.
12. Norrman J, Brookes AJ, Yates C, St Clair D. Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease. Br J Psychiatry. 1995;167:533-536.
FREE FULL TEXT
13. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology. 1995;45:1323-1328.
FREE FULL TEXT
14. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology. 1996;47:444-448.
FREE FULL TEXT
15. Kurz A, Egensperger R, Haupt M, et al. Apolipoprotein E 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology. 1996;47:440-443.
FREE FULL TEXT
16. Asada T, Kariya T, Yamagata Z, Kinoshita T, Asaka A. Apolipoprotein E 4 allele and cognitive decline in patients with Alzheimer's disease. Neurology. 1996;47:603.
FREE FULL TEXT
17. Bondi MW, Salmon DP, Monsch AU, et al. Episodic memory changes are associated with the ApoE-4 allele in nondemented older adults. Neurology. 1995;45:2203-2206.
FREE FULL TEXT
18. Hooijer C, Dinkgreve M, Jonker C, Lindeboom J. Short screening tests for dementia in the elderly population, I: a comparison between AMTS, MMSE, MSQ and SPMSQ. Int J Geriatr Psychiatry. 1992;7:559-571.
FULL TEXT
|
ISI
19. Launer LJ, Dinkgreve MAHM, Jonker C, Hooijer C, Lindeboom L. Are age and education independent correlates of the Mini-Mental State Exam performance of community-dwelling elderly? J Gerontol. 1993;48:P271-P277.
20. Folstein MF, Folstein S, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
FULL TEXT
|
ISI
| PUBMED
21. Roth M, Huppert FA, Tym E, Mountjoy CQ. CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly. New York, NY: Cambridge University Press; 1988.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan DL. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
FREE FULL TEXT
24. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24:637-639.
ISI
| PUBMED
25. Havekes L, De Knijff P, Beiseigel U, et al. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987;28:455-463.
ABSTRACT
26. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.11. Cary, NC: SAS Institute Inc; 1996:531-656.
27. Evans DE, Beckett LA, Field TS, et al. Apolipoprotein E 4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 1997;277:822-824.
FREE FULL TEXT
28. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol. 1995;38:6-14.
FULL TEXT
|
ISI
| PUBMED
29. Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E 4 allele and the lifetime risk of Alzheimer's disease. Arch Neurol. 1995;52:1074-1079.
FREE FULL TEXT
30. Roses AD, Strittmatter WJ, Pericak-Vance MA, et al. Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet. 1994;343:1564-1565.
FULL TEXT
|
ISI
| PUBMED
31. Ma J, Yee A, Brewer HB, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92-94.
FULL TEXT
| PUBMED
32. Strittmatter WJ, Weisgraber KH, Goedert M, et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol. 1994;125:163-171.
FULL TEXT
|
ISI
| PUBMED
33. Ohm TG, Kirca M, Bohl J, et al. Apolipoprotein E polymorphism influences not only senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience. 1995;66:583-587.
FULL TEXT
|
ISI
| PUBMED
34. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer disease. Annu Rev Med. 1996;47:387-400.
FULL TEXT
|
ISI
| PUBMED
35. Plassman BL, Breitner JCS. Apolipoprotein E and cognitive decline in Alzheimer's disease. Neurology. 1996;47:317-320.
FREE FULL TEXT
36. Bird TD. Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view. Ann Neurol. 1995;38:2-4.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Apolipoprotein E and Alzheimer Disease
John H. Growdon
Arch Neurol. 1998;55(8):1053-1054.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of Family History and Apolipoprotein E {varepsilon}4 Status on Cognitive Decline in the Absence of Alzheimer Dementia: The Cache County Study
Hayden et al.
Arch Neurol 2009;66:1378-1383.
ABSTRACT
| FULL TEXT
APOE-{epsilon}4, Depressive Symptoms, and Cognitive Decline in Chinese Older Adults: Singapore Longitudinal Aging Studies
Niti et al.
J Gerontol A Biol Sci Med Sci 2009;64A:306-311.
ABSTRACT
| FULL TEXT
Dementia of the Alzheimer Type
Jalbert et al.
Epidemiol Rev 2008;30:15-34.
ABSTRACT
| FULL TEXT
APOE {varepsilon}4 allele predicts faster cognitive decline in mild Alzheimer disease
Cosentino et al.
Neurology 2008;70:1842-1849.
ABSTRACT
| FULL TEXT
Invited Commentary: When Bad Genes Look Good--APOE*E4, Cognitive Decline, and Diagnostic Thresholds
Glymour
Am J Epidemiol 2007;165:1239-1246.
ABSTRACT
| FULL TEXT
Brain structural alterations before mild cognitive impairment
Smith et al.
Neurology 2007;68:1268-1273.
ABSTRACT
| FULL TEXT
APOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model
Martins et al.
Neurology 2005;65:1888-1893.
ABSTRACT
| FULL TEXT
Apolipoprotein E {epsilon}4 and Change in Cognitive Functioning in Community-Dwelling Older Adults
Swan et al.
J Geriatr Psychiatry Neurol 2005;18:196-201.
ABSTRACT
Predictive Utility of Apolipoprotein E Genotype for Alzheimer Disease in Outpatients With Mild Cognitive Impairment
Devanand et al.
Arch Neurol 2005;62:975-980.
ABSTRACT
| FULL TEXT
Apolipoprotein E, B Vitamins, and Cognitive Function in Older Adults
Bunce et al.
Journals of Gerontology Series B: Psychological Sciences and Social Science 2005;60:P41-P48.
ABSTRACT
| FULL TEXT
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
Lane and Farlow
J. Lipid Res. 2005;46:949-968.
ABSTRACT
| FULL TEXT
Apolipoprotein E {varepsilon}4 Allele and Lorazepam Effects on Memory in High-Functioning Older Adults
Pomara et al.
Arch Gen Psychiatry 2005;62:209-216.
ABSTRACT
| FULL TEXT
Impact of APOE in mild cognitive impairment
Farlow et al.
Neurology 2004;63:1898-1901.
ABSTRACT
| FULL TEXT
APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging
Bunce et al.
Neurology 2004;63:816-821.
ABSTRACT
| FULL TEXT
Improved brief assessment of cognition in aging and dementia
Lindeboom et al.
Neurology 2004;63:543-546.
ABSTRACT
| FULL TEXT
The role of APOE-{epsilon}4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging
Bretsky et al.
Neurology 2003;60:1077-1081.
ABSTRACT
| FULL TEXT
The Apolipoprotein E {epsilon}4 Allele and Decline in Different Cognitive Systems During a 6-Year Period
Wilson et al.
Arch Neurol 2002;59:1154-1160.
ABSTRACT
| FULL TEXT
Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women
Cohen et al.
Neurology 2001;57:2223-2228.
ABSTRACT
| FULL TEXT
The effects of APOE genotype on age at onset and progression of neurodegenerative diseases
Chapman et al.
Neurology 2001;57:1482-1485.
ABSTRACT
| FULL TEXT
A gender difference in the association between APOE genotype and age-related cognitive decline
Mortensen and Hogh
Neurology 2001;57:89-95.
ABSTRACT
| FULL TEXT
Apolipoprotein E Genotypes and the Incidence of Alzheimer's Disease among Persons Aged 75 Years and Older: Variation by Use of Antihypertensive Medication?
Guo et al.
Am J Epidemiol 2001;153:225-231.
ABSTRACT
| FULL TEXT
Dementia, Quantitative Neuroimaging, and Apolipoprotein E Genotype
Bigler et al.
Am. J. Neuroradiol. 2000;21:1857-1868.
ABSTRACT
| FULL TEXT
Genetics and visual attention: Selective deficits in healthy adult carriers of the varepsilon 4 allele of the apolipoprotein E gene
Greenwood et al.
Proc. Natl. Acad. Sci. USA 2000;97:11661-11666.
ABSTRACT
| FULL TEXT
Depression and risk of cognitive decline and Alzheimer's disease: Results of two prospective community-based studies in The Netherlands
GEERLINGS et al.
Br. J. Psychiatry 2000;176:568-575.
ABSTRACT
| FULL TEXT
APOE-{epsilon}4 is associated with memory decline in cognitively impaired elderly
Dik et al.
Neurology 2000;54:1492-1497.
ABSTRACT
| FULL TEXT
Cognitive Function and Apolipoprotein E in Very Old Adults: Findings From the Nun Study
Riley et al.
Journals of Gerontology Series B: Psychological Sciences and Social Science 2000;55:69S-75.
ABSTRACT
| FULL TEXT
Preclinical memory decline in cognitively normal apolipoprotein E-{epsilon}4 homozygotes
Caselli et al.
Neurology 1999;53:201-201.
ABSTRACT
| FULL TEXT
Association Between Memory Complaints and Incident Alzheimer's Disease in Elderly People With Normal Baseline Cognition
Geerlings et al.
Am. J. Psychiatry 1999;156:531-537.
ABSTRACT
| FULL TEXT
Other articles noted
Evid. Based Ment. Health 1999;2:8-8.
FULL TEXT
Apolipoprotein E and Alzheimer Disease
Growdon
Arch Neurol 1998;55:1053-1054.
FULL TEXT
|
